Effect of six candidate genes on early aging in a French population

Aging Clinical and Experimental Research

Volumn 15, Issue 2, 2003, Pages 111-116

  Xia, Yongjing ^a   Gueguen, René ^a   Vincent Viry, Monique ^a   Siest, Gérard ^a   Visvikis, Sophie ^a  

^a Centre de Medecine Preventive   (France)

Author keywords

Aging; Candidate genes; Genetic polymorphism; Paraoxonase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CHOLESTEROL; CYSTATHIONINE BETA SYNTHASE; DIPEPTIDYL CARBOXYPEPTIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ADULT; AGED; AGING; ALLELE; ARTICLE; BIOASSAY; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FRANCE; GENE ACTIVITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0038044911     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324487     Document Type: Article

References (30)

1. Schächter F, Faure-Delanef L, Guenot F, et al. Genetic associations with human longevity at the APOE and ACE loci. Nature Genetics 1994; 6: 29-32.
2. Luoma PV. Gene activation, apolipoprotein AI-/high density lipoprotein, atherosclerosis prevention and longevity. Pharmacol Toxicol 1997; 81: 57-64.
3. Siest G, Pillot T, Regis-Bailly A, et al. Apolipoprotein E: An important gene and protein to follow in laboratory medicine. Clin Chem 1995; 41: 1068-86.
4. Stengard JH, Weiss KM, Sing CF. An ecological study of association between coronary heart disease mortality rates in men and the relative frequencies of common allelic variations in the gene coding for apolipoprotein E. Hum Genet 1998; 103: 234-41.
5. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Proc Natl Acad Sci USA 1995; 92: 4725-7.
6. Kervinen K, Savolainen MJ, Salokannel J, et al. Apolipoprotein E and B polymorphisms-longevity factors assessed in nonagenarians. Atherosclerosis 1994; 105: 89-95.
7. Blanche H, Cabanne L, Sahbatou M, Thomas G. A study of French centenarians: are ACE and APOE associated with longevity? Life Science 2001; 324: 129-35.
8. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51: 197-205.
9. Krege JH, Moyer JS, Langenbach LL, et al. Angiotensin-converting enzyme gene and atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:1245-50.
10. Kang SS, Wong PW. Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Atherosclerosis 1996; 119: 135-8.
11. Jemaa R, Fumeron F, Poirier O, et al. Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. J Lipid Res 1995; 36: 2141-6.
12. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
13. Laplaud PM, Dantoine T, Chapman MJ. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin Chem Lab Med 1998; 36: 431-41.
14. Gueguen R. Proposition of an aging indicator from general health examination in France. Clin Chem Lab Med 2002; 40: 235-9.
15. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
16. Dingeon B, Thome H. Enzyme de conversion de l'angiotensine: dosage automatique sur analyseur centrifuge COBAS-BIO et COBAS-FARA, ou pourquoi faire cher et compliqué quand on peut faire simple et économique. ISB 1990; 16: 201-6 (in French).
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
18. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-8.
19. Evans AE, Poirier O, Kee F, et al. Polymorphisms of the angiotensin-converting-enzyme in subjects who die from coronary heart disease. Q J Med 1994; 87: 211-4.
20. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
21. Cheng S, Pallaud C, Grow MA, et al. A multilocus genotyping assay for cardiovascular disease. Clin Chem Lab Med 1998; 36: 561-6.
22. Bohnet K, Régis-Bailly A, Vincent-Viry M, Gueguen R, Siest G, Visvikis S. Apolipoprotein E genotype E4/E2 in the STANISLAS cohort study. Dominance of the epsilon2 allele? Ann Hum Genet 1996; 60: 509-16.
23. Pallaud C, Maurice M, Cheng S, et al. Multilocus approach to cardiovascular risk. Scand J Clin Lab Invest 1999; 59: 168-76.
24. 447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis 1998; 140: 89-95.
25. Siest G, Visvikis S, Herbeth B, et al. Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas cohort. Clin Chem Lab Med 1998; 36: 35-42.
26. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998; 31: 329-36.
27. Heijmans BT, Westendorp RGJ, Lagaay AM, Knook DL, Kluft C, Slagboom PE. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis 2000; 149: 91-7.
28. Brattström L, Zhang Y, Hurtig M, et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis 1998; 141: 315-19.
29. Heijmans BT, Westendorp RGJ, Slagboom PE. Common gene variants, mortality and extreme longevity in humans. Exp Gerontol 2000; 35: 865-77.
30. Strandberg TE, Valvanne J, Erkinjuntti T, Sorva A, Tilvis RS. Serum lipids, health, and one-year mortality in randomized age cohorts of 75, 80, and 85 years: the Helsinki Ageing Study. Nutr Metab Cardiovasc Dis 1992; 2: 101-5.